Protocol Ledger

NCT04124926 · Phase III · COMPLETED

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

Interventional Phase III clinical trial protocol NCT04124926 sponsored by Phathom Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-28 Enrollment: 1,027 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04124926
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,027 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04124926
Protocol FieldVerified Registry Value
NCT IdentifierNCT04124926
Consolidated Lead SponsorPhathom Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment1,027 participants (ACTUAL)
Registered Start Date2019-10-28
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI